142 related articles for article (PubMed ID: 11929349)
1. Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction.
Darbà J; Izquierdo I; Pontes C; Navas C; Rovira J
Pharmacoeconomics; 2002; 20(3):195-201. PubMed ID: 11929349
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
Cruz-Fernández JM; López-Bescós L; García-Dorado D; López García-Aranda V; Cabadés A; Martín-Jadraque L; Velasco JA; Castro-Beiras A; Torres F; Marfil F; Navarro E
Eur Heart J; 2000 Mar; 21(6):457-65. PubMed ID: 10681486
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
Kalantzi KI; Ntalas IV; Chantzichristos VG; Tsoumani ME; Adamopoulos D; Asimakopoulos C; Bourdakis A; Darmanis P; Dimitriadou A; Gkiokas S; Ipeirotis K; Kitikidou K; Klonaris I; Kostaki A; Logothetis D; Mainas K; Mais T; Maragiannis A; Martiadou K; Mavronasos K; Michelongonas I; Mitropoulos D; Papadimitriou G; Papadopoulos A; Papaioakeim M; Sofillas K; Stabola S; Stefanakis E; Stergiou D; Thoma M; Zenetos A; Zisekas S; Goudevenos JA; Panagiotakos DB; Tselepis AD
Curr Vasc Pharmacol; 2019; 17(6):635-643. PubMed ID: 29866011
[TBL] [Abstract][Full Text] [Related]
4. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.
Matías-Guiu J; Ferro JM; Alvarez-Sabín J; Torres F; Jiménez MD; Lago A; Melo T;
Stroke; 2003 Apr; 34(4):840-8. PubMed ID: 12649515
[TBL] [Abstract][Full Text] [Related]
5. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study.
Culebras A; Rotta-Escalante R; Vila J; Domínguez R; Abiusi G; Famulari A; Rey R; Bauso-Tosselli L; Gori H; Ferrari J; Reich E;
Neurology; 2004 Apr; 62(7):1073-80. PubMed ID: 15079004
[TBL] [Abstract][Full Text] [Related]
6. Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation.
Murdoch D; Plosker GL
Drugs; 2006; 66(5):671-92. PubMed ID: 16620146
[TBL] [Abstract][Full Text] [Related]
7. Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
Alvarez-Sabín J; Quintana M; Santamarina E; Maisterra O
Cerebrovasc Dis; 2014; 37(3):181-7. PubMed ID: 24503927
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
Gianetti J; Gensini G; De Caterina R
Thromb Haemost; 1998 Dec; 80(6):887-93. PubMed ID: 9869155
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study of the effect of low-dosage acetylsalicylic acid and triflusal in the prevention of cardiovascular events among young adults with ischemic cerebrovascular disease].
Matías-Guiu J; Alvarez-Sabín J; Codina A
Rev Neurol; 1997 Nov; 25(147):1669-72. PubMed ID: 9484514
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: results of a Spanish multicenter trial. Grupo de Estudio del Triflusal en la Angina Inestable.
Plaza L; López-Bescós L; Martín-Jadraque L; Alegría E; Cruz-Fernández JM; Velasco J; Ruipérez JA; Malpartida F; Artal A; Cabadés A
Cardiology; 1993; 82(6):388-98. PubMed ID: 8402761
[TBL] [Abstract][Full Text] [Related]
11. Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke.
Alvarez-Sabín J; Penalba A; Quintana M; Krupinski J; García-Bonilla L; Montaner J
Cerebrovasc Dis; 2009; 28(4):371-7. PubMed ID: 19641312
[TBL] [Abstract][Full Text] [Related]
12. Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial.
Shin S; Kim KJ; Cho IJ; Hong GR; Jang Y; Chung N; Rah YM; Chang HJ
Yonsei Med J; 2015 Sep; 56(5):1227-34. PubMed ID: 26256964
[TBL] [Abstract][Full Text] [Related]
13. Triflusal.
McNeely W; Goa KL
Drugs; 1998 Jun; 55(6):823-33; discussion 834-5. PubMed ID: 9617597
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.
Falco A; Salvati F; Vitacolonna E; Avellone G; Pinto A; Di Febbo C; Ballone E; Di Nicola M; Ciabattoni G; Davì G
Atherosclerosis; 2005 Dec; 183(2):329-35. PubMed ID: 16285996
[TBL] [Abstract][Full Text] [Related]
15. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
Chambers M; Hutton J; Gladman J
Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of atrial fibrillation patients in the NASPEAF study. Prospective evaluation of different antiplatelet treatments.
Bover R; Pérez-Gómez F; Maluenda MP; Asenjo S; Pérez-Saldaña R; Igea A; Suárez M; Coleto D; Fernández C
Rev Esp Cardiol; 2009 Sep; 62(9):992-1000. PubMed ID: 19712620
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
19. Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial.
Szucs TD; Meyer BJ; Kiowski W
Eur Heart J; 1999 Sep; 20(17):1253-60. PubMed ID: 10454977
[TBL] [Abstract][Full Text] [Related]
20. Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate.
Marissal JP; Selke B; Lebrun T
Pharmacoeconomics; 2000 Aug; 18(2):185-200. PubMed ID: 11067652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
